Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes pill tested in chinese patients – early safety results expected

NCT ID NCT07073170

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new daily pill called LY3549492 in 36 Chinese adults with type 2 diabetes. The main goal was to check safety and side effects over about 18 weeks. Participants had diabetes for at least 6 months and were on diet, exercise, or stable metformin. This is a first step to see if the drug is safe enough for larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

36 people

The number who actually took part.

Started

Jul 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are native Chinese * Have type 2 diabetes for at least 6 months * Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months * Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10% * Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2 * Have had a stable body weight for the 3 months prior to screening * Women must not be of childbearing potential Exclusion Criteria: * Have type 1 diabetes or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization * Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness * Have a clinically significant gastric emptying abnormality * Have or have a history of pancreatitis * Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease * Have a personal or family history of multiple endocrine neoplasia syndrome type 2 or medullary thyroid carcinoma * Have an uncontrolled endocrine abnormality * Have an abnormal blood pressure or pulse rate * Have a 12-lead electrocardiogram (ECG) abnormality * Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Peking University First Hospital

    Dongcheng District, 100009, China

  • Peking University People's Hospital

    Beijing, 100033, China

  • West China Hospital of Sichuan University

    Chengdu, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.